The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
Abstract
PURPOSE: To evaluate the toxicity, pharmacokinetics, immunogenicity, and antitumor activity of anti-Tac(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an antibody Fv fragment fused to truncated Pseudomonas exotoxin. PATIENTS AND METHODS: Patients with CD25+hematologic malignancies for whom standard and salvage therapies failed were treated with LMB-2 at dose levels that ranged from 2 to 63 μg/kg administered intravenously over 30 minutes on alternate days for three doses (QOD × 3). RESULTS: LMB-2 was administered to 35 patients for a total of 59 cycles. Dose-limiting toxicity at the 63 μg/kg level was reversible and included transaminase elevations in one patient and diarrhea and cardiomyopathy in another. LMB-2 was well tolerated in nine patients at the maximum-tolerated dose (40 μg/kg QOD × 3); toxicity was transient and most commonly included transaminase elevations (eight patients) and fever (seven patients). Only six of 35 patients developed significant neutralizing antibodies after the first cycle. The median half-life was 4 hours. One hairy cell leukemia (HCL) patient achieved a complete remission, which is ongoing at 20 months. Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three patients), chronic lymphocytic leukemia (one patient), Hodgkin’s disease (one patient), and adult T-cell leukemia (one patient). Responding patients had 2 to 5 log reductions of circulating malignant cells, improvement in skin lesions, and regression of lymphomatous masses and splenomegaly. All four patients with HCL responded to treatment. CONCLUSION: LMB-2 has clinical activity in CD25+hematologic malignancies and is relatively nonimmunogenic. It is the first recombinant immunotoxin to induce major responses in cancer. LMB-2 and similar agents that target other cancer antigens merit further clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
Allured, V. S., Collier, R. J., Carroll, S. F., & McKay, D. B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1320 · Cited by 515
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
Chaudhary, V. K., Queen, G., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., & Pastan, I. (1989) · Nature · doi:10.1038/339394a0 · Cited by 413
Self-citationLong-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Saven, A., Burian, C., Koziol, J. A., & Piro, L. D. (1998) · Blood · doi:10.1182/blood.v92.6.1918 · Cited by 329
Nussenblatt, R. B., Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7462 · Cited by 259
Self-citationAmlot, P., Stone, M., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., & Ghetie, V (1993) · Blood · doi:10.1182/blood.v82.9.2624.2624 · Cited by 235
LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F. M., Platanias, L. C., Schwartz, G. N., Ratain, M. J., Rook, A. H., Freytes, C. O., Craig, F. E., et al. (1998) · PubMed · doi:10.1182/blood.v91.2.399 · Cited by 184
Brinkmann, U., Brinkmann, E., Gallo, M., & Pastan, I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10427 · Cited by 173
Self-citationSerotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion
Grossbard, M., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L. J., Spector, N., Dear, K. B. G., Lambert, J., & Blättler, W. A. (1992) · Blood · doi:10.1182/blood.v79.3.576.576 · Cited by 171
Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blättler, W. A., & Epstein, C. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.726 · Cited by 159
Cheson, B. D., Sorensen, J. M., Vena, D. A., Montello, M. J., BARRETT, J. A., Damasio, E. E., Tallman, M. S., Annino, L., Connors, J. M., Coiffier, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3007 · Cited by 156
Kreitman, R. J., & Pastan, I. H. (1995) · Biochemical Journal · doi:10.1042/bj3070029 · Cited by 154
Self-citationStone, M., Sausville, E., Fay, J. W. J., Headlee, D. J., Collins, R., Figg, W. D., Stetler-Stevenson, M. A., Jain, V. K., Jaffe, E., Solomon, D., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1188.bloodjournal8841188 · Cited by 139
Self-citationKreitman, R. J., Bailon, P., Chaudhary, V. K., FitzGerald, D., & Pastan, I. (1994) · Blood · doi:10.1182/blood.v83.2.426.426 · Cited by 138
Self-citationChiron, M. F., Fryling, C. M., & FitzGerald, D. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32431-6 · Cited by 129
Acute Hepatotoxicity of Pseudomonas aeruginosa Exotoxin A in Mice Depends on T Cells and TNF
Schümann, J., Angermüller, S., Bang, R., Lohoff, M. D., & Tiegs, G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5745 · Cited by 91
Sheibani, K., Winberg, C. D., van de Velde, S., Blayney, D. W., & Rappaport, H. (1987) · PubMed · Cited by 80
Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Willingham, M. C., FitzGerald, D. J., & Pastan, I. H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8291 · Cited by 78
Self-citationImmunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch, T. J., Lambert, J., Coral, F., Shefner, J. M., Wen, P. Y., Blättler, W. A., Collinson, A. R., Ariniello, P. D., Braman, G. M., Cook, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.723 · Cited by 70
Hartmann, F., Horak, E. M., Garmestani, K., Wu, C., Brechbiel, M. W., Kozak, R. W., Tso, J. Y., Kosteiny, S. A., Gansow, O. A., & Nelson, D. L. (1994) · PubMed · Cited by 70
Duvic, M. A., Cather, J. C., Maize, J. C., & Frankel, A. E. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199805)58:1<87::aid-ajh18>3.0.co;2-2 · Cited by 68
Cardiodepression by tumor necrosis factor-alpha.
Müller‐Werdan, U., Engelmann, H., & Werdan, K. (1998) · PubMed · Cited by 62
Multani, P. S., O'Day, S. J., Nadler, L. M., & Grossbard, M. L. (1998) · PubMed · Cited by 61
Siegall, C. B., Liggitt, D., Chace, D. F., Mixan, B. J., Sugai, J. V., Davidson, T., & Steinitz, M. (1997) · PubMed · Cited by 46
Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu, H., Baxter, L. T., & Jain, R. K. (1997) · PubMed · Cited by 43
Kreitman, R. J., & Pastan, I. H. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00024a025 · Cited by 24
Self-citationAutocrine and Paracrine Regulation of Neoplastic Cell Growth in Hairy Cell Leukemia
Schmid, M., & Porzsolt, F. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509056850 · Cited by 14
Cited by
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Self-citationBeyond natural antibodies: the power of in vitro display technologies
Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1791 · Cited by 545
Metadata
- Authors
- Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-08
- Volume
- 18
- Issue
- 8
- Pages
- 1622-1636
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112628345
- Cited by
- 420
- References
- 30
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.